Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 79, Issue 1, 2012, Pages 59-67

  Kirma, Cevat ^a   Erkol, Ayhan ^b   Pala, Selçuk ^a   Oduncu, Vecih ^a   Dündar, Cihan ^a   Izgi, Akin ^a   Tigen, Kürş ^a   Gibson, C Michael ^c  

^a KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^b Kardiyoloji Klini i   (Turkey)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiplatelets; microcirculation; primary angioplasty

Indexed keywords

TIROFIBAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY FLOW RESERVE; CORONARY VASCULAR RESISTANCE; DRUG MEGADOSE; FEMALE; HEART CATHETERIZATION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HUMAN; INTRACORONARY INFUSION; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 84255202793     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23109     Document Type: Article

References (29)

1. Niccoli G, Burzotta F, Galiuto L, Crea F,. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
2. de Lemos JA, Warner JJ,. New tools for assessing microvascular obstruction in patients with ST elevation myocardial infarction. Heart 2004; 90: 119-120. (Pubitemid 38147130)
3. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC,. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008; 51: 560-565.
4. Sezer M, Oflaz H, Gören T, Okçular I, Umman B, Nişanci Y, Bilge AK, Sanli Y, Meriç M, Umman S,. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007; 356: 1823-1834. (Pubitemid 46698463)
5. Sezer M, Cimen A, Aslanger E, Elitok A, Umman B, Buǧra Z, Yormaz E, Türkmen C, Adalet IS, Nişanci Y, Umman S,. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol 2009; 54: 1065-1071.
6. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ,. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 2005; 293: 1759-1765.
7. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E,. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28: 443-449. (Pubitemid 47343560)
8. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R,; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare metal stent for acute myocardial infarction: A randomized trial. JAMA 2005; 293: 2109-2117. (Pubitemid 40617063)
9. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R,; MULTISTRATEGY Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799. (Pubitemid 351549970)
10. Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER,. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: A meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv 2009; 2: 230-236.
11. De Luca G, Ucci G, Cassetti E, Marino P,. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-analysis. J Am Coll Cardiol 2009; 53: 1668-1673.
12. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ,. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials. Eur Heart J 2010; 31: 35-49.
13. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO,. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
14. Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E,; INTEGRITI Study Group. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 2004; 110: 679-684. (Pubitemid 39056266)
15. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G,. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118: 49-57.
16. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM,. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: The intracoronary Eptifibatide (ICE) trial. Circulation 2010; 121: 784-791.
17. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, Huang LP, Wang LX,. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008; 72: 1605-1609.
18. Yang TY, Chang ST, Chung CM, Cheng NJ,. Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment. Int Heart J 2005; 46: 139-145.
19. Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, Fileti L, Ferrari R,; 3T/2R Investigators. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: The 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). J Am Coll Cardiol 2010; 55: 255-256.
20. Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, Wong G, Buller C, Ricci D, Mancini GB, Fung A,. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: A BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. JACC Cardiovasc Interv 2008; 1: 654-659.
21. Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M,. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93. (Pubitemid 32973418)
22. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A,. Intracoronary stenting and antithrombotic regimen-rapid early action for coronary treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238.
23. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ,. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-2578. (Pubitemid 32521967)
24. Danzi GB, Capuano C, Sesana M, Baglini R,. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Res Opin 2003; 19: 28-33. (Pubitemid 36378317)
25. Schrör K, Weber AA,. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80. (Pubitemid 37498175)
26. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM,; TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: Observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006; 47: 2374-2379. (Pubitemid 43866383)
27. Fung AY, Saw J, Starovoytov A, Densem C, Jokhi P, Walsh SJ, Fox RS, Humphries KH, Aymong E, Ricci DR, Webb JG, Hamburger JN, Carere RG, Buller CE,. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009; 53: 837-845.
28. Kini AS, Chen VH, Krishnan P, Lee P, Kim MC, Mares A, Suleman J, Moreno PR, Sharma SK,. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2008; 156: 513-519.
29. Bertrand OF, Rodés-Cabau J, Larosse E, Nguyen CM, Roy L, Déry JP, Courtis J, Nault I, Poirier P, Costerousse O, De Larochellie're R,. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hr infusion in the randomized early discharge after transradial stenting of coronary arteries (EASY) study. Am Heart J 2008; 156: 135-140.